Indications and usage:
Recent clinical data indicate that ESAFOSFINA (FDP) is beneficial in patients with myocardial infarction, in the treatment of shock and regional ischemia and in severe ischemia of lower limbs.
ESAFOSFINA is indicated in hypophosphatemia associated with metabolic impairment (malabsorption, severe burns and total parenteral nutrition), in 2,3-diphosphoglycerate depletion following multiple transfusions, and during extracorporeal circulation in cardiac surgery.
Presentation: Box of 1 vial + 1 injection pack + 1 infusion sets
Storage condition: Store below 30 degrees C.
Shelf life: 60 months from manufacturing date
Manufactured by: BIOMEDICA FOSCAMA GROUP S.P.A – ITALY